Autobio Diagnostics Co., Ltd.
603658
Peringkat dalam Saham
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Harga Saham
$5.15
Terakhir disinkronkan: 2026-10-22
Kapitalisasi Pasar
$2.94B
Perubahan (1 hari)
0.97%
Perubahan (1 tahun)
-5.80%
Negara
CN
Perdagangan Autobio Diagnostics Co., Ltd. (603658)
Kategori
Healthcare
Laba untuk Autobio Diagnostics Co., Ltd. (603658)
Laba pada Jun 2026 TTM: $169.22M
Menurut laporan keuangan terbaru dari Autobio Diagnostics Co., Ltd., laba saat ini perusahaan adalah $169.22M. Pada tahun 2024, perusahaan memperoleh laba sebesar $176.60M, penurunan dibandingkan dengan laba tahun 2023 sebesar $192.49M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Autobio Diagnostics Co., Ltd. dari 2011 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $169.22M | -3.17% |
| 2025 | $174.77M | -1.04% |
| 2024 | $176.60M | -8.25% |
| 2023 | $192.49M | 2.63% |
| 2022 | $187.55M | 11.87% |
| 2021 | $167.65M | 29.68% |
| 2020 | $129.28M | 1.63% |
| 2019 | $127.20M | 33.67% |
| 2018 | $95.16M | 20.21% |
| 2017 | $79.16M | 34.78% |
| 2016 | $58.73M | 17.42% |
| 2015 | $50.02M | 28.06% |
| 2014 | $39.06M | 63.96% |
| 2013 | $23.82M | 27.82% |
| 2012 | $18.64M | 63.64% |
| 2011 | $11.39M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $7.87B | 4,550.10% |
US
|
|
| $4.82B | 2,747.14% |
US
|
|
| $-252.70M | -249.33% |
US
|
|
| $4.12B | 2,335.02% |
CN
|
|
| $1.66B | 879.78% |
US
|
